Traphaco and Daewoong Embark on a New Chapter in Technology Transfer Cooperation

On October 13, 2026, Traphaco Joint Stock Company and Daewoong Pharmaceutical (South Korea) held a kick-off meeting for the second batch of Phase 3 technology transfer products at Traphaco Hưng Yên Co., Ltd. The event marked a new milestone in the partnership between the two companies, contributing to the realization of Traphaco’s strategy to develop high-quality modern pharmaceuticals.

Representing Traphaco at the event were CEO Đào Thúy Hà; Deputy General Directors Kim Dong Hyu and Nguyễn Huy Văn; the management team of Traphaco Hưng Yên Co., Ltd.; and representatives from the Research and Development, Technology Transfer, Quality Management, Business, and Marketing departments. The Daewoong delegation included Mr. Cha Jun Woo, Head of Global Business at Daewoong and Member of Traphaco’s Board of Directors; Mr. Jo Young Ho, Director of the Daewoong India Research Center; Mr. Oh Tae Won, Head of Formulation Research at Daewoong Pharmaceutical in South Korea; along with Daewoong’s research and analytical testing experts.

Traphaco CEO Đào Thúy Hà and Deputy General Director Kim Dong Hyu deliver remarks at the event

Speaking at the event, Ms. Đào Thúy Hà, General Director of Traphaco, emphasized that Vietnam’s pharmaceutical industry is entering a new stage of development, with increasingly stringent requirements for product quality, research and development capabilities, manufacturing technologies, and production facility standards. Against this backdrop, Traphaco remains committed to maintaining its leading strengths in traditional herbal medicines while accelerating the development of high-quality modern pharmaceuticals, bioequivalent medicines, and technology-transferred products, alongside its strategic orientation toward establishing an EU-GMP-compliant manufacturing facility.

Throughout this journey, Daewoong has remained one of Traphaco’s key strategic partners. The two companies began their technology transfer cooperation in 2019. By 2026, they had signed cooperation agreements covering a total of 34 products across three phases, while continuing discussions to expand their collaborative portfolio in subsequent phases. To date, Traphaco has obtained marketing authorizations for 16 technology-transferred pharmaceutical products, of which 13 have been launched in the market. Sales revenue from technology-transferred products reached VND 27 billion in the first nine months of 2026 and is projected to reach approximately VND 38 billion for the full year.

Mr. Cha Jun Woo, Head of Global Business at Daewoong and Member of Traphaco’s Board of Directors, shares his insights on the technology transfer cooperation between Traphaco and Daewoong over the past years

Speaking at the kick-off meeting, Mr. Cha Jun Woo noted that technology transfer activities have made a positive contribution to strengthening Traphaco’s competitiveness. Daewoong reaffirmed its commitment to supporting Traphaco throughout the entire process, from trial production and preparation of regulatory registration dossiers to product commercialization. Furthermore, the two companies have agreed on a roadmap to continue their technology transfer cooperation through Phase 8, with an increasing focus on differentiated generic medicines and fixed-dose combination products.

The event further reinforced the longstanding and close partnership between Traphaco and Daewoong. Building on the achievements to date, the combination of international technological expertise and domestic manufacturing and distribution strengths is expected to enable Traphaco to progressively develop a portfolio of high-quality modern pharmaceuticals, enhance its competitiveness, and generate new momentum for sustainable growth in the years ahead.

Further strengthening the longstanding partnership between Traphaco and Daewoong